TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of the Safety and Efficacy of Intravenous Iron vs Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding
Brief Summary: This study compares of the safety and efficacy of intravenous iron vs oral iron in the treatment of anemia secondary to heavy uterine bleeding


Options:
A: Arm Label: Ferric Carboxymaltose (FCM); Type: EXPERIMENTAL; Interventions: Drug: Ferric Carboxymaltose (FCM) | Arm Label: Ferrous Sulfate tablets; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ferrous Sulfate tablets | Intervention Type: DRUG; Name: Ferric Carboxymaltose (FCM); Assigned to Arm(s): Ferric Carboxymaltose (FCM) | Intervention Type: DRUG; Name: Ferrous Sulfate tablets; Assigned to Arm(s): Ferrous Sulfate tablets
B: Arm Label: Iron Group; Type: EXPERIMENTAL; Interventions: Drug: Ferrous Sulfate | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: Ferrous Sulfate; Assigned to Arm(s): Iron Group | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo Group
C: Intervention Type: DRUG; Name: Iron Sucrose IV 200mg, once a week, for 5 weeks; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ferrous sulfate 200mg PO TID, for 8 weeks; Assigned to Arm(s): N/A
D: Arm Label: Ferumoxytol; Type: EXPERIMENTAL; Interventions: Drug: Ferumoxytol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Ferumoxytol; Assigned to Arm(s): Ferumoxytol | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of the Safety and Efficacy of Intravenous Iron vs Oral Iron in Subjects Who Display Postpartum Anemia
Brief Summary: This study compares the safety and efficacy of intravenous iron vs oral iron in subjects who display postpartum anemia.


Options:
A: Arm Label: Iron isomaltoside 1000 (Monofer®); Type: EXPERIMENTAL; Interventions: Drug: Iron isomaltoside 1000 | Arm Label: Standard medical Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard medical Care | Intervention Type: DRUG; Name: Iron isomaltoside 1000; Assigned to Arm(s): Iron isomaltoside 1000 (Monofer®) | Intervention Type: OTHER; Name: Standard medical Care; Assigned to Arm(s): Standard medical Care
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: red blood cell transfusion | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: red blood cell transfusion | Intervention Type: PROCEDURE; Name: red blood cell transfusion; Assigned to Arm(s): 1, 2
C: Arm Label: VIT-45; Type: EXPERIMENTAL; Interventions: Drug: VIT-45 | Arm Label: Oral iron tablets; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral iron tablets | Intervention Type: DRUG; Name: Oral iron tablets; Assigned to Arm(s): Oral iron tablets | Intervention Type: DRUG; Name: VIT-45; Assigned to Arm(s): VIT-45
D: Arm Label: Red blood cell transfusion; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Red blood cell transfusion

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Simvastatin and Metformin on Clinical, Endocrine, Metabolic and Endothelial Function of Women With Polycystic Ovary Syndrome: Prospective Randomised Trial
Brief Summary: The purpose of this study is to compare effects of statins (simvastatin) and metformin on clinical (menstrual cycle, excessive hair, skin problems), endocrine (androgens), metabolic (lipids, markers of systemic inflammation), and endothelial function parameters in women with polycystic ovary syndrome (PCOS).


Options:
A: Arm Label: Atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: Lipitor | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lipitor; Assigned to Arm(s): Atorvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Simvastatin and Metformin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Simvastatin and Metformin on Clinical, Endocrine, Metabolic and Endothelial Function of Women With Polycystic Ovary Syndrome: Prospective Randomised Trial
Brief Summary: The purpose of this study is to compare effects of statins (simvastatin) and metformin on clinical (menstrual cycle, excessive hair, skin problems), endocrine (androgens), metabolic (lipids, markers of systemic inflammation), and endothelial function parameters in women with polycystic ovary syndrome (PCOS).


Options:
A: Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Metformin plus spironolactone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin plus Spironolactone | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Metformin plus Spironolactone; Assigned to Arm(s): Metformin plus spironolactone
B: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Simvastatin and Metformin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Open-label, Single-arm Study of the Efficacy and Safety of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
Brief Summary: The primary objective of this study was to compare the time between paracenteses before and after administration of Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) in ovarian cancer participants with symptomatic malignant ascites.

The secondary objectives were to further assess efficacy and safety of Aflibercept treatment, and the exploratory objectives were to assess pharmacokinetics, immunogenicity and health-related quality of life.


Options:
A: Arm Label: Pazopanib/Paclitaxel association; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib, Drug: Paclitaxel | Arm Label: Paclitaxel alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib/Paclitaxel association | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Paclitaxel alone, Pazopanib/Paclitaxel association
B: Arm Label: Aflibercept; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept
C: Arm Label: BI 6727; Type: EXPERIMENTAL; Interventions: Drug: BI 6727 | Arm Label: Cytotoxic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Gemcitabine, Drug: Topotecan, Drug: Pegylated liposomal doxorubicin (PLD) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: Topotecan; Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: Pegylated liposomal doxorubicin (PLD); Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: BI 6727; Assigned to Arm(s): BI 6727
D: Arm Label: Cohort 1; Type: OTHER; Interventions: Drug: M200 (Volociximab), Drug: Liposomal Doxorubicin | Arm Label: Cohort 2; Type: OTHER; Interventions: Drug: Liposomal Doxorubicin, Drug: M200 (Volociximab) | Arm Label: Group A; Type: OTHER; Interventions: Drug: Liposomal Doxorubicin | Arm Label: Group B; Type: OTHER; Interventions: Drug: Liposomal Doxorubicin, Drug: M200 (Volociximab) | Arm Label: Group C; Type: OTHER; Interventions: Drug: Liposomal Doxorubicin, Drug: M200 (Volociximab) | Intervention Type: DRUG; Name: M200 (Volociximab); Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: Liposomal Doxorubicin; Assigned to Arm(s): Cohort 1, Cohort 2, Group A, Group B, Group C | Intervention Type: DRUG; Name: M200 (Volociximab); Assigned to Arm(s): Cohort 2, Group C | Intervention Type: DRUG; Name: M200 (Volociximab); Assigned to Arm(s): Group B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIb, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Existence of Horizontal Transmission of the RIX4414 Vaccine Strain Between Twins Within a Family.
Brief Summary: The aim of this study is to explore horizontal transmission of the HRV (Human Rotavirus) vaccine strain within a family from the twin vaccinated with Rotarix to the twin receiving placebo. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Options:
A: Arm Label: Rotavin; Type: EXPERIMENTAL; Interventions: Drug: Rotavin | Intervention Type: DRUG; Name: Rotavin; Assigned to Arm(s): Rotavin
B: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix TM | Intervention Type: BIOLOGICAL; Name: Rotarix TM; Assigned to Arm(s): Rotarix Group
C: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Rotarix, Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Placebo Group, Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group
D: Arm Label: Primary 1: Rotavirus vaccine 6 and 10 weeks; Type: ACTIVE_COMPARATOR; Interventions: Biological: Rotavirus vaccine | Arm Label: Primary 1: Rotavirus vaccine 6, 10 and 14 weeks; Type: EXPERIMENTAL; Interventions: Biological: Rotavirus vaccine | Arm Label: Primary 1: Rotavirus vaccine 10 and 14 weeks; Type: EXPERIMENTAL; Interventions: Biological: Rotavirus vaccine | Arm Label: Primary 2: Rotavirus vaccine withholding breast feeding; Type: EXPERIMENTAL; Interventions: Biological: Rotavirus vaccine | Arm Label: Primary 2: Rotavirus vaccine with immediate breast feeding; Type: EXPERIMENTAL; Interventions: Biological: Rotavirus vaccine | Arm Label: Baseline seroconversion for rotavirus; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Rotavirus vaccine; Assigned to Arm(s): Primary 1: Rotavirus vaccine 10 and 14 weeks, Primary 1: Rotavirus vaccine 6 and 10 weeks, Primary 1: Rotavirus vaccine 6, 10 and 14 weeks, Primary 2: Rotavirus vaccine with immediate breast feeding, Primary 2: Rotavirus vaccine withholding breast feeding

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIb, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Existence of Horizontal Transmission of the RIX4414 Vaccine Strain Between Twins Within a Family.
Brief Summary: The aim of this study is to explore horizontal transmission of the HRV (Human Rotavirus) vaccine strain within a family from the twin vaccinated with Rotarix to the twin receiving placebo. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Options:
A: Arm Label: Group 1, RotaTeq® x 3; Type: ACTIVE_COMPARATOR; Interventions: Biological: RotaTeq® | Arm Label: Group 5, Rotarix®, RotaTeq® x2; Type: EXPERIMENTAL; Interventions: Biological: Rotarix®, Biological: RotaTeq® | Arm Label: Group 4, Rotarix® x 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Rotarix® | Arm Label: Group 2, RotaTeq®, Rotarix® x 2; Type: EXPERIMENTAL; Interventions: Biological: Rotarix®, Biological: RotaTeq® | Arm Label: Group 3, RotaTeq® x 2, Rotarix®; Type: EXPERIMENTAL; Interventions: Biological: Rotarix®, Biological: RotaTeq® | Intervention Type: BIOLOGICAL; Name: Rotarix®; Assigned to Arm(s): Group 2, RotaTeq®, Rotarix® x 2, Group 3, RotaTeq® x 2, Rotarix®, Group 4, Rotarix® x 2, Group 5, Rotarix®, RotaTeq® x2 | Intervention Type: BIOLOGICAL; Name: RotaTeq®; Assigned to Arm(s): Group 1, RotaTeq® x 3, Group 2, RotaTeq®, Rotarix® x 2, Group 3, RotaTeq® x 2, Rotarix®, Group 5, Rotarix®, RotaTeq® x2
B: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Rotarix, Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Placebo Group, Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group
C: Arm Label: Rotarix 3-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™ | Arm Label: Rotarix 2-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™, Biological: Placebo | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix™; Assigned to Arm(s): Rotarix 2-Dose Group, Rotarix 3-Dose Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group, Rotarix 2-Dose Group
D: Intervention Type: BIOLOGICAL; Name: Rotavirus; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIb, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Existence of Horizontal Transmission of the RIX4414 Vaccine Strain Between Twins Within a Family.
Brief Summary: The aim of this study is to explore horizontal transmission of the HRV (Human Rotavirus) vaccine strain within a family from the twin vaccinated with Rotarix to the twin receiving placebo. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Options:
A: Arm Label: 1; Type: OTHER; Interventions: Biological: Rotateq vaccine | Intervention Type: BIOLOGICAL; Name: Rotateq vaccine; Assigned to Arm(s): 1
B: Arm Label: Group 1, RotaTeq® x 3; Type: ACTIVE_COMPARATOR; Interventions: Biological: RotaTeq® | Arm Label: Group 5, Rotarix®, RotaTeq® x2; Type: EXPERIMENTAL; Interventions: Biological: Rotarix®, Biological: RotaTeq® | Arm Label: Group 4, Rotarix® x 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Rotarix® | Arm Label: Group 2, RotaTeq®, Rotarix® x 2; Type: EXPERIMENTAL; Interventions: Biological: Rotarix®, Biological: RotaTeq® | Arm Label: Group 3, RotaTeq® x 2, Rotarix®; Type: EXPERIMENTAL; Interventions: Biological: Rotarix®, Biological: RotaTeq® | Intervention Type: BIOLOGICAL; Name: Rotarix®; Assigned to Arm(s): Group 2, RotaTeq®, Rotarix® x 2, Group 3, RotaTeq® x 2, Rotarix®, Group 4, Rotarix® x 2, Group 5, Rotarix®, RotaTeq® x2 | Intervention Type: BIOLOGICAL; Name: RotaTeq®; Assigned to Arm(s): Group 1, RotaTeq® x 3, Group 2, RotaTeq®, Rotarix® x 2, Group 3, RotaTeq® x 2, Rotarix®, Group 5, Rotarix®, RotaTeq® x2
C: Intervention Type: BIOLOGICAL; Name: Rotavirus; Assigned to Arm(s): N/A
D: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Rotarix, Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Placebo Group, Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Indicated Prevention With Omega-3 Fatty Acids in Adolescents With 'At-Risk-Mental-State' for Psychosis: A Randomised, Double Blind, Placebo-Controlled Treatment Trial
Brief Summary: Early intervention in psychosis might be associated with better outcomes. However, intervention in the pre-psychotic phase has been questioned as, using current criteria, only 20-50% of individuals classified as prodromal develop a psychotic disorder within a 1-2 years period. Treatment agents investigated in the pre-psychotic phase of schizophrenia and other psychotic disorders should, therefore, not have major side effects. This proposal investigates omega-3 fatty acids (1.2 gramm per day eicosapentaenoic acid/docosahexaenoic acid;EPA/DHA) as a beneficial and possible preventive therapeutic agent in young people at ultra high-risk for developing a psychotic disorder.


Options:
A: Arm Label: Relaxation group; Type: ACTIVE_COMPARATOR; Interventions: Other: Relaxation group | Arm Label: Psychoeducational group; Type: EXPERIMENTAL; Interventions: Behavioral: Interventional group : PEPSUI psychoeducational program | Intervention Type: BEHAVIORAL; Name: Interventional group : PEPSUI psychoeducational program; Assigned to Arm(s): Psychoeducational group | Intervention Type: OTHER; Name: Relaxation group; Assigned to Arm(s): Relaxation group
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Omega 3 fatty acids | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Omega 3 fatty acids | Intervention Type: DRUG; Name: Omega 3 fatty acids; Assigned to Arm(s): A, B
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: Behavioral: Dialectical Cognitive Therapy | Intervention Type: BEHAVIORAL; Name: Dialectical Cognitive Therapy; Assigned to Arm(s): 1
D: Intervention Type: BEHAVIORAL; Name: Dialectical Behavioral Therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Indicated Prevention With Omega-3 Fatty Acids in Adolescents With 'At-Risk-Mental-State' for Psychosis: A Randomised, Double Blind, Placebo-Controlled Treatment Trial
Brief Summary: Early intervention in psychosis might be associated with better outcomes. However, intervention in the pre-psychotic phase has been questioned as, using current criteria, only 20-50% of individuals classified as prodromal develop a psychotic disorder within a 1-2 years period. Treatment agents investigated in the pre-psychotic phase of schizophrenia and other psychotic disorders should, therefore, not have major side effects. This proposal investigates omega-3 fatty acids (1.2 gramm per day eicosapentaenoic acid/docosahexaenoic acid;EPA/DHA) as a beneficial and possible preventive therapeutic agent in young people at ultra high-risk for developing a psychotic disorder.


Options:
A: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Family-aided Assertive Community Treatment; Type: EXPERIMENTAL; Interventions: Drug: aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine, Behavioral: Psychoeducational multifamily group treatment, Behavioral: Supported employment and education | Intervention Type: DRUG; Name: aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine; Assigned to Arm(s): Family-aided Assertive Community Treatment | Intervention Type: BEHAVIORAL; Name: Psychoeducational multifamily group treatment; Assigned to Arm(s): Family-aided Assertive Community Treatment | Intervention Type: BEHAVIORAL; Name: Supported employment and education; Assigned to Arm(s): Family-aided Assertive Community Treatment
B: Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy (CBT); Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Supportive Counselling (SC); Assigned to Arm(s): N/A
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Omega 3 fatty acids | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Omega 3 fatty acids | Intervention Type: DRUG; Name: Omega 3 fatty acids; Assigned to Arm(s): A, B
D: Arm Label: BI 409306; Type: EXPERIMENTAL; Interventions: Drug: BI 409306 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BI 409306; Assigned to Arm(s): BI 409306 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase IV Study of Early RA: a Randomized Magnetic Resonance Imaging Study Comparing the Effects of Methotrexate Alone or in Combination With Infliximab or Intravenous Pulse Methylprednisolone
Brief Summary: The purpose of the study is to compare the effects of methotrexate (MTX) alone or in combination with intravenous (IV) methylprednisolone (MP) or infliximab (IFX) on MRI-detected synovitis, bone edema and erosive changes in early rheumatoid arthritis (RA) patients.


Options:
A: Arm Label: SWITCH; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tocilizumab | Arm Label: ADD-ON; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tocilizumab plus methotrexate | Intervention Type: DRUG; Name: Tocilizumab plus methotrexate; Assigned to Arm(s): ADD-ON | Intervention Type: DRUG; Name: Tocilizumab; Assigned to Arm(s): SWITCH
B: Intervention Type: DRUG; Name: Certolizumab Pegol; Assigned to Arm(s): N/A
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: conventional DMARD combination | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Biological: MTX plus anti-TNF | Intervention Type: DRUG; Name: conventional DMARD combination; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: MTX plus anti-TNF; Assigned to Arm(s): B
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab, methylprednisolone, methotrexate, Drug: Methotrexate | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab, methylprednisolone, methotrexate, Drug: Methotrexate + Methylprednisolone | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab, methylprednisolone, methotrexate, Drug: Methotrexate + Infliximab | Intervention Type: DRUG; Name: Infliximab, methylprednisolone, methotrexate; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Methotrexate + Methylprednisolone; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Methotrexate + Infliximab; Assigned to Arm(s): C

Answer: D